

Herantis Pharma to Participate in the Upcoming Investor Conferences

Herantis Pharma Plc, Press Release, 29 September 2021 at 12:00 EEST

Herantis Pharma Plc (“Herantis”), focusing on disease modifying therapies for debilitating neurodegenerative diseases, today announced that Dr. Craig Cook, Chief Executive Officer, will hold 1x1 meetings and have a company presentation at the following investor conferences:

Sachs 21st Annual Biotech in Europe Forum, October 7th - 8th, 2021, Digital Conference

1x1 meetings and virtual presentation

Redeye Neurology Seminar CNS – October 13th, 2021

Virtual Presentations at 10:00 – 13:00 EEST / 9:00 – 12:00 CEST

Antti Vuolanto, Chief Operating Officer will have a company presentation at:

Turun Talouspäivät: Säästä ja Sijoita – October 22nd – 23rd, 2021

All presentations will be available via a digital library, which is accessible to event participants only. Please contact the organizers at the Sachs, Redeye, and Turun Talouspäivät if you wish to attend and/or schedule a meeting with Herantis.

For more information, please contact:

Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: ir@herantis.com

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400

Company website: www.herantis.com

About Herantis Pharma Plc

Herantis focuses on disease modifying therapies for debilitating neurodegenerative diseases by restoring the neuronal protective mechanism of proteostasis, a key system in neurodegenerative disease. Proteostasis regulates proteins within the body and influences the fate of every protein from synthesis to degradation. Its failure results in a vicious cycle of pathological accumulation of protein aggregates, neuroinflammation and various forms of cellular stress that is widely implicated with the development of many neurodegenerative diseases including Parkinson’s Disease, Alzheimer’s and other diseases. CDFN (a biological protein) is Herantis’ lead program and a clinical stage asset; and HER-096 (a synthetic peptide version of CDFN) is Herantis’ follow-on program. CDFN is a natural protein that occurs naturally in the body whose natural role is to protect neurons by balancing and supporting proteostasis, thereby preventing and counteracting disease generating mechanisms. Herantis is taking this natural ability and harnessing it as a treatment for neurodegenerative disease. Both CDFN and HER-096, via their multimodal mechanism of action, have the potential to improve neuronal survival and stop the progression of Parkinson’s and other neurodegenerative diseases with a significant therapeutic impact on the quality of patients’ lives.

The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First

North Growth Market Sweden. For more information, please visit <https://www.herantis.com>